|

CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA

RECRUITINGSponsored by AstraZeneca
Actively Recruiting
SponsorAstraZeneca
Started2025-10-15
Est. completion2029-12-30
Eligibility
Age19 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06927648

Summary

To fulfil the post-approval commitment of MFDS to conduct post-marketing surveillance, this study is designed to assess the known safety profile, identify previously unsuspected adverse reactions and to evaluate the effectiveness of Capivasertib under conditions of routine daily medical practice in Korea.

Eligibility

Age: 19 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients eligible for and treated with the study drug according to the approved label in South Korea
* Patients who provide signed and dated written informed consent, either personally or through a legally acceptable representative.

Exclusion Criteria:

* Participation in any interventional trial during the treatment of the study drug
* Other off-label indications according to the approved label in South Korea

Conditions2

Breast CancerCancer

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.